Hepatic morphological alterations induced by zidovudine (ZDV) in an experimental model

Pathology Research and Practice

Volumn 192, Issue 2, 1996, Pages 182-187

  Corcuera, T ^a,c   Alonso, M J ^a   Picazo, A ^a   Gomez F ^a   Roldan M ^a   Abad, M ^b   Munoz E ^b   López Bravo, Antonio ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c Servicio de Enfermedades Infecciosas   (Spain)

Author keywords

Electron microscopy; Hepatocytes; Mitochondria; Rat; Zidovudine ZDV

Indexed keywords

ANTIVIRUS AGENT; FAT; GLYCOGEN; ZIDOVUDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ULTRASTRUCTURE; CONTROLLED STUDY; LIVER CELL; LIVER TOXICITY; MITOCHONDRION; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; ROUGH ENDOPLASMIC RETICULUM; SMOOTH ENDOPLASMIC RETICULUM; ULTRASTRUCTURE; VIRUS REPLICATION;

EID: 0030002975     PISSN: 03440338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0344-0338(96)80218-4     Document Type: Article

References (29)

1. Abrams DI (1990) Alternative therapies in HIV Infection. AIDS 4: 1179-1187
2. Arias J, Lorente L, Aller MA et al (1993) Cirugia hépatica experimental. Ed Kronos. "Fármacos e hígado", pp 161-172
3. Bessen LJ, Greene JB, Loui E, Seitzman P, Weinberg H (1988) Severe polymiositis syndrome associated with zidovudine therapy or AIDS and ARC. N Engl J Med 318: 708
4. Bodel L, Riegel S (1988) Zidovudine-associated myopathy. Lancet 2: 689-690
5. Chen SC, Barker SM, Mitchell DH et al (1992) Concurrent zidovudine-induced myopathy and hepatotoxicity in patients treated for human immunodeficiency virus (HIV) infection. Pathol 24 (2):109-111
6. Corcuera MT, López-Bravo A, Martínez-Rodriguez R et al (1994) Histochemical and ultrastructural changes induced by zidovudine in mitochondria of rat cardiac muscle. Eur J Histochem 38: 311-318
7. Cretton EM, Xie MY, Bevan RJ, Gondgaon NM, Scinazi RF (1991) Catabolism of 3′-azido-3′-deoxythymidine in hepatocytes and liver microsomes, with evidence of formation of 3′-amino-3′-deoxythymidine, a highly toxic catabolite for human bone marrow cells. Mol Pharmacol 39 (2): 258-266
8. Fischl MA, Richman DD, Grieco MH (1987) The efficacy of AZT in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 317 (4): 185-191
9. Freiman JP, Helfert KE, Hamrell MP, Stein DS (1993) Hepatomegaly with severe steatosis in HIV-seropositive patients. AIDS 7 (3): 379-385
10. Furman PA, Barry DW (1988) Spectrum of antiviral activity and mechanism of action of zidovudine Am J Med 85: 176-181 (Supl 2A).
11. Gonzalez Lahoz J, Najera R (1993) Estado actual y perspectivas fúturas de la terapia antirretrovírica anti VIH. Pub Ofic Soc Española Interdisciplinaria de SIDA 4 (8): 443-446
12. Gragera R, Saborido A, Molano F et al (1993) Ultrastructural changes inducted by anabolic steroids in liver of trained rats. Histol Histopath 8: 449-455
13. Hortwizt JP, Chua J, Met N et al (1964) Nucleosides V. The monomeryslates of 1-(2′-deoxides b-D-Lyxofuranoxyl) thimine. J Org Chem 29; 2076-2078
14. Kawczynski W, Czochraska B, Shuger D (1993) Electrochemical reduction products of azido nucleosides, including zidovudine (AZT). Mechanisms and revelance to their intracellular metabolism. Acta Biocim Pol 40 (2): 213-223
15. Lamperth L, Dalakas MC, Dagani E, Anderson J, Ferrari R (1991) Abnormal skeletal and cardiac muscle mitochondria induced by (AZT) in human muscle in vitro and in animal model. Lab Invest 65 (6): 742-751
16. Lewis W, Papoian T, Gonzalez B et al (1991) Mitochondrial ultrastructural and molecular changes induced by zidovudine in rats hearts. Lab Inves 65(2): 228-236
17. Lewis W, Gónzalez B, Chomyn A, Papoian T (1992) Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondria. J Clin Invest 89: 1354-1360
18. Mitsuya H, Weinhold KJ, Furman PA et al (1985) 3′azido-3′deoxythymidine (BWA509U): An antiviral agent that inhibits the infectivity and cytopatic effect of human T-Lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Sci, pp 7096-7100
19. Montaner JS, Gelmon JS, Tsoukas C (1990) The effect of zidovudine on plateled count in HIV-infected individuals. J Acq Imm Def Syn 3: 565-570
20. Ostertag W, Roesler G, Krieg CJ et al (1974) Induction of endogenous virus and of thimidine kinase by bromodeoxyuridine in cell cultures transformed by Friends virus. Proc Natl Acad Sci 72: 4980-4985
21. Panegyres PK, Papadimitriou JM, Hollingsworth PN et al (1990) Vesicular changes in the myopathies of AIDS. Ultrastructural observations and their relationship to zidovudine treatment. J Neurol Neurosurg Psychiatry 53 (8): 659-655
22. Reyes MG, Casanova J, Varrichio F et al (1991) Zidovudine mitochondriopathy of hamster quadrics muscle. Lab Invest 64: 89A
23. Richman DD, Grimes JM, Lagacoko SS (1990) Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of Human immunodeficiency virus. J Acq Imm Def Syn 3: 743-746
24. a Ed Vol II. Ed Interamericana. "Hígado y las vias biliares" p 959-1015
25. Ruprecht RM, Chou TC, Chipty F et al (1990) Interferon-1-and- 3′-Azido-3′-deoxythimidine are highly synergistic in mice and prevent viremia after acute retrovirus exposure. J Acq Imm Def Syn 3: 594-601
26. Stambuck D, Youle M, Hawkins D et al (1984) The efficacy and toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex (ARC): and open uncontrolled treatment study. Q J Med 70: 161-174
27. Tomelleri G, Tonin P, Spadaro M et al (1992) AZT-induced mitochondrial myopathy. Ital J Neurol Sci 13 (9): 723-728
28. Wright R, Alberti KGM, Karran S, Milward-Sadler GH (1979) Liver and biliary disease. Pathophysiology. diagnosis. In: The liver and drugs, pp 822-847. W. B. Saunders Company Ltd, London, Philadelphia, Toronto
29. Yarchoan R, Klecker R, Weinhold KJ et al (1986) Administration of 3′-azido-3′-deoxy thymidine, an inhibitor of HTLV-III/LAV repliction, to patients with AIDS or AIDS-related complex. Lancet 15: 575-580